Form 4: Pfizer Executive Modifies Stock Appreciation Rights

Executive Vice President Michael McDermott modifies stock appreciation rights (SARs) to extend vesting and settlement dates.

Summary

• Michael McDermott, an Executive Vice President at Pfizer Inc., modified his stock appreciation rights (SARs) on September 12, 2024.
• The modification extends the vesting and settlement dates of certain outstanding SARs by two years.
• This was done through a one-time offer by Pfizer to modify eligible TSRUs (total shareholder return units).
• McDermott elected to modify 45,920 SARs with an original exercisable/expiration date of 02/23/2028 to an exercisable/expiration date of 02/23/2030.
• He also modified 34,234 SARs with an original exercisable/expiration date of 02/24/2027 to an exercisable/expiration date of 02/24/2029.
• The grant price and the number of shares underlying the modified SARs remain unchanged.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, with a neutral sentiment.

Positives

• The modification of SARs provides the executive with a longer timeframe to benefit from potential stock appreciation.
• The modification offer itself could be seen as a positive sign, indicating Pfizer's commitment to incentivizing its executives.

Future Outlook

The document does not contain specific forward-looking statements regarding Pfizer's overall financial performance or future outlook beyond the modification of the executive's stock appreciation rights.

Industry Context

Executive compensation adjustments, such as the modification of stock appreciation rights, are common in the pharmaceutical industry to align executive incentives with long-term shareholder value creation. These adjustments can be influenced by company performance, industry trends, and regulatory changes.

Comparison to Industry Standards

• Stock appreciation rights are a common component of executive compensation packages in large pharmaceutical companies like Pfizer.
• Companies like Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation to incentivize their executives.
• The specific terms of these awards, such as vesting schedules and performance metrics, can vary widely based on company-specific factors and industry benchmarks.

Stakeholder Impact

• The modification of stock appreciation rights could potentially impact shareholders by aligning executive incentives with long-term stock performance.
• The modification has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates